Nielsen Andreas F, Al-Hamdani Ali, Rasmussen Jeppe V, Olsen Bo S
Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, Hellerup, Denmark.
Department of Clinical Medicine, University of Copenhagen, København N, Denmark.
JSES Int. 2022 Jul 2;6(5):713-722. doi: 10.1016/j.jseint.2022.06.002. eCollection 2022 Sep.
Open reduction and internal fixation (ORIF) is the standard treatment for multifragmentary intra-articular distal humeral fractures. Fractures not amenable by ORIF are treated with total elbow arthroplasty (TEA). In recent years, elbow hemiarthroplasty (EHA) has been used as an alternative to TEA, as weight bearing restrictions and risk of component loosening are lower. We systematically reviewed the literature reporting functional outcomes and complication rates after either EHA or ORIF for Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association (AO/OTA) type 13C fractures.
We searched PubMed, Embase, The Cochrane Library, and Scopus. The inclusion criteria were at least 5 patients, aged ≥50 years, AO/OTA type 13C fracture treated with ORIF or EHA, and evaluation with the Mayo Elbow Performance Score. Literature screening and data extraction were conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. The results were synthesized qualitatively using weighted means. No comparative statistical analyses were done.
We included 27 articles, which included 96 patients treated with EHA and 535 patients treated with ORIF. We identified 1 randomized controlled trial and 26 case series. The weighted mean Mayo Elbow Performance Score was 86.9 (n = 89) in the EHA group and 84.7 (n = 535) in the ORIF group. There were 26 (33%) complications (n = 78) in the EHA group and 103 (38%) complications (n = 270) in the ORIF group. Complication rates were generally high in both groups.
We found comparable results of EHA and ORIF, which indicate that EHA is a viable treatment option for AO/OTA type 13C fractures not amenable by ORIF. Because of high risk of bias, interpretation of the results should be done with caution.
切开复位内固定术(ORIF)是治疗肱骨远端关节内多片段骨折的标准方法。无法通过ORIF治疗的骨折则采用全肘关节置换术(TEA)。近年来,肘关节半关节成形术(EHA)已被用作TEA的替代方法,因为其负重限制和假体松动风险较低。我们系统回顾了关于 Arbeitsgemeinschaft für Osteosynthesefragen/骨科创伤协会(AO/OTA)13C型骨折采用EHA或ORIF治疗后功能结果和并发症发生率的文献。
我们检索了PubMed、Embase、Cochrane图书馆和Scopus。纳入标准为至少5例患者,年龄≥50岁,采用ORIF或EHA治疗的AO/OTA 13C型骨折,以及采用梅奥肘关节功能评分进行评估。根据系统评价和Meta分析的首选报告项目(PRISMA)声明进行文献筛选和数据提取。结果采用加权均值进行定性合成。未进行比较统计分析。
我们纳入了27篇文章,其中包括96例接受EHA治疗的患者和535例接受ORIF治疗的患者。我们确定了1项随机对照试验和26个病例系列。EHA组的加权平均梅奥肘关节功能评分为86.9(n = 89),ORIF组为84.7(n = 535)。EHA组有26例(33%)并发症(n = 78),ORIF组有103例(38%)并发症(n = 270)。两组的并发症发生率总体都较高。
我们发现EHA和ORIF的结果相当,这表明EHA是无法通过ORIF治疗的AO/OTA 13C型骨折的一种可行治疗选择。由于存在较高的偏倚风险,对结果的解释应谨慎进行。